Table 2.
Data for natural history, effectiveness, adverse events, and costs.
| Input parameter | Value | Source (references) |
|---|---|---|
| Treatment effectiveness | ||
| Probability of staying on 1st-line chemotherapy | Weibull, shape: 1.17, scale: 53.15 | [14, 15] |
| Probability of staying on 1st-line bosutinib | Weibull, shape: 0.92, scale: 54.79 | [13, 16–18] |
| Probability of staying on 1st-line dasatinib | Weibull, shape: 0.92, scale: 102.4 | [19–21] |
| Probability of staying on 1st-line imatinib | Weibull, shape: 0.92, scale: 79.65 | [13, 16–24] |
| Probability of staying on 1st-line nilotinib | Weibull, shape: 0.92, scale: 106 | [22–24] |
| Probability of staying on 2nd-line bosutinib | Exponential, 0.97 | [25, 26] |
| Probability of staying on 2nd-line dasatinib | Exponential, 0.98 | [27–29] |
| Probability of staying on 2nd-line nilotinib | Exponential, 0.97 | [30–33] |
| Probability of staying on 2nd-line ponatinib | Exponential, 0.97 | [34–37] |
| Probability of staying in CP on chemotherapy after TKI failure | Exponential, 0.01 | [38] |
| Probability of staying in AP on chemotherapy | Exponential, 0.11 | [39] |
| Probability of dying from CML in BP on chemotherapy | Exponential, 0.09 | [38] |
| Utilities | ||
| Chronic phase | 0.92 × (age-dependent utility general population) | [40–42] |
| Accelerated phase | 0.79 × (age-dependent utility general population) | [41, 42] |
| Blast phase | 0.57 × (age-dependent utility general population) | [41, 42] |
| After SCT without GvHD | 0.98 × (age-dependent utility general population) | [42, 43] |
| After SCT with GvHD | 0.9 × (age-dependent utility general population) | [42, 43] |
| Drug cost | ||
| Imatinib 1st line 400 mg qd | $10,057.04 per month | [44] |
| Dasatinib 1st line 100 mg qd | $11,021.20 per month | [44] |
| Nilotinib 1st line 300 mg bid | $10,436.08 per month | [44] |
| Bosutinib 1st line 500 mg qd | $11,277.36 per month | [44] |
| Dasatinib 2nd line 100 mg qd | $11,021.20 per month | [44] |
| Nilotinib 2nd line 400 mg bid | $10,436.00 per month | [44] |
| Bosutinib 2nd line 500 mg qd | $11,277.36 per month | [44] |
| Ponatinib 2nd line 45 mg qd | $12,611.04 per month | [44] |
| Hydroxyurea 2000 mg qd | $655.24 per month | [44] |
| Tacrolimus 2 mg/day | $313.20 per month | [44] |
| Mycophenolate 2000 mg/day | $1,887.35 per month | [44] |
| Therapy cost | ||
| Outpatient in CP | $162.52 per month | [40, 45] |
| Inpatient in CP | $323.09 per month | [40, 45] |
| Outpatient in AP | $261.98 per month | [40, 45] |
| Inpatient in AP | $2,173.10 per month | [40, 45] |
| Outpatient in BP | $261.98 per month | [40, 45] |
| Inpatient in BP | $1,890.59 per month | [40, 45] |
| Stem-cell transplantation and its complication | ||
| Acute GvHD | $66,821.50 | [46] |
| Chronic GvHD | $10,082.11 | [46] |
| Follow-up care within the first year after SCT | $556.15 per month | [40, 45], clinical expert opinion |
| Follow-up care beyond the first year after SCT | $485.61 per month | [40, 45], clinical expert opinion |
| Transplant from live related donor (occurs just once) | $90,234.54 | [47] |
| Transplant from live unrelated donor (occurs just once) | $131,976.34 | [47] |
| Adverse events | ||
| Abdominal pain | $5,176.34 per inpatient stay | [47] |
| Anemia | $4,919.15 per inpatient stay | [47] |
| Diarrhea | $5,389.65 per inpatient stay | [47] |
| Hypertension | $6,845.76 per inpatient stay | [47] |
| Leukocytopenia | $6,424.44 per inpatient stay | [47] |
| Neutropenia | $8,400.54 per inpatient stay | [47] |
| Pancreatitis | $7,656.35 per inpatient stay | [47] |
| Rash | $3,915.32 per inpatient stay | [47] |
| Thrombocytopenia | $5,846.95 per inpatient stay | [47] |
AP: accelerated phase; bid: twice a day; BP: blast phase; CML: chronic myeloid leukemia; CP: chronic phase; GvHD: graft-versus-host disease; qd: every day; SCT: stem cell transplantation.